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A Cholecystokinin B Receptor-Specific Aptamer Does Not Activate Receptor
Signaling
Abstract
Targeted nanoparticles which deliver effective doses of chemotherapeutic drugs directly to pancreatic
tumors could improve treatment efficacy without the toxicities associated with systemic drug
administration. One protein on tumor cells that can be targeted by nanoparticles is a G-protein coupled
cell surface receptor, the cholecystokinin B receptor (CCKBR). Previously, we had shown that attaching
the CCKBR ligand gastrin to the surface of nanoparticles can enhance their up-take by tumors. The
drawback of using gastrin is that it can also activate the receptor, causing tumor cell growth. This study
shows that a DNA aptamer that binds to the CCKBR and enhances nanoparticle up-take by tumors does
not activate this receptor.
PANC-1 cells, a cultured human pancreatic cancer cell line, were treated for 24 h with CCKBR aptamer
1153. Cell lysates were run on Bis-Tris gels, transferred to membranes, blocked in 5% BSA and incubated
overnight with primary antibodies, including antibodies directly against phosphorylated-Akt (Ser473), total
Akt, and beta-actin, a protein loading control. Although the CCKBR aptamer 1153 is internalized by
pancreatic cancer cells in a receptor-mediated fashion, it does not stimulate cell proliferation. Because of
this, we anticipate that it will not activate CCKBR signaling. If aptamer 1153 does not activate
downstream receptor signaling, our future work will test whether the aptamer could be used to
specifically direct drug-containing nanoparticles to tumors, making chemotherapy treatments for
pancreatic cancer patients more effective with fewer off-target effects and toxicity.
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ABSTRACT
Targeted nanoparticles which deliver effective doses of chemotherapeutic drugs directly
to pancreatic tumors could improve treatment efficacy without the toxicities associated with
systemic drug administration. One protein on tumor cells that can be targeted by nanoparticles is
a G-protein coupled cell surface receptor, the cholecystokinin B receptor (CCKBR). Previously,
we had shown that attaching the CCKBR ligand gastrin to the surface of nanoparticles can
enhance their up-take by tumors. The drawback of using gastrin is that it can also activate the
receptor, causing tumor cell growth. This study shows that a DNA aptamer that binds to the
CCKBR and enhances nanoparticle up-take by tumors does not activate this receptor.
PANC-1 cells, a cultured human pancreatic cancer cell line, were treated for 24 h with
CCKBR aptamer 1153. Cell lysates were run on Bis-Tris gels, transferred to membranes,
blocked in 5% BSA and incubated overnight with primary antibodies, including antibodies
directly against phosphorylated-Akt (Ser473), total Akt, and beta-actin, a protein loading control.
Although the CCKBR aptamer 1153 is internalized by pancreatic cancer cells in a receptormediated fashion, it does not stimulate cell proliferation. Because of this, we anticipate that it
will not activate CCKBR signaling. If aptamer 1153 does not activate downstream receptor
signaling, our future work will test whether the aptamer could be used to specifically direct drugcontaining nanoparticles to tumors, making chemotherapy treatments for pancreatic cancer
patients more effective with fewer off-target effects and toxicity.
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